Skip to main content
. Author manuscript; available in PMC: 2015 Feb 15.
Published in final edited form as: Clin Cancer Res. 2013 Dec 18;20(4):985–994. doi: 10.1158/1078-0432.CCR-13-1999

Figure 2.

Figure 2

Plasma and liver metformin and imatinib concentrations in Oct1-deficient mice. A, plasma concentrations of imatinib in wild-type (black circles) and Oct1/2(−/−) knockout mice (open circles) after tail vein injection of imatinib (50 mg/kg). Animals were sacrificed at indicated time points. Data are means ± SD of 5 (1, 5, 10 minutes) or 2 (30 minutes) animals per group. B, plasma and liver metformin (left scale) and imatinib (right scale) concentrations after tail vein injection of metformin (i.v., 5 mg/kg) or imatinib (i.v. 50 mg/kg) into wild-type or Oct1/2(−/−) knockout mice or after oral gavage to wild-type or Oct1(−/−) knockout mice (imatinib oral, 50 mg/kg). Animals were sacrificed after 10 minutes and 60 minutes after i.v. or oral application, respectively. Data are means ± SD of animals treated with imatinib (n=5) or metformin.